Search Site | Index

About Lymphoma | Advocacy | Art | CAM | Clinical trials 
Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms |
Tests | Treatments | Types of Lymphoma | How to Help

Find Clinical Trial

 by Agent

by Type of Lymphoma & Treatment Status  

Trials of Interest

New trials since October 2018

Phase I since 2017  | Phase III since 2008

Guidelines at Diagnosis | About Clinical Trials

evidence-based support and information


 About Lymphoma > Leukemic Phase

Last update: 03/13/2014


A "leukemic or blastoid phase" is a finding of unusual high amounts of lymphocytes in the peripheral blood (lymphocytosis) suggesting that the lymphoma cells are in the blood in high concentrations.

lymphocytosis is an abnormal increase in the number of lymphocytes a type of white blood cell in your blood. The most common cause is viral infection, such as EBV, CMV, rubella, whooping cough, toxoplasmosis, brucellosis, chronic lymphatic leukaemiam, and leukemic phase lymphoma.

It's our impression that special attention must be paid to tumor lysis syndrome when treating lymphoma in the leukemic phase - because the tumor cells may respond very rapidly to treatment, stressing the body to eliminate the cells killed (lysis) by therapy. 

Related articles

  1. Leukemic phase of B-cell lymphomas mimicking chronic lymphocytic leukemia and variants at presentation. Mod Pathol. 2002 Nov;15(11):1111-20. PMID: 12429788 | Related articles
  2. Leukemic phase of mantle cell lymphoma, blastoid variant.
    Am J Clin Pathol. 1999 Apr;111(4):495-500. PMID: 10191769 | Related articles
  3. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias. Leukemia. 1999 Nov;13(11):1721-6. PMID: 10557044
  4. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease.
    Eur J Haematol. 2005 Apr;74(4):353-8. PMID: 15777349  | Related articles

    This report presents a rare case of long-term survivor of MCL with a progression of the original MCL cell clone to MCL-BV and demonstrates the clinical value of quantitative minimal residual disease assessment for optimized therapeutic management.
  5. Mantle Cell Lymphomas, blastic variant - Related PubMed articles


Disclaimer:  The information on is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns, you should always consult your doctor. 
Copyright 2004,  All Rights Reserved.